BioCardia Readies FDA Submission for CardiAMP Trial Data

BioCardia is preparing to submit its CardiAMP cell therapy for FDA approval, following the completion of three clinical trials. The company's CEO, Peter Altman, highlighted the clinical benefit of the therapy, with the latest Phase III results presented as a late-breaking clinical trial. The submission is imminent, with regulatory catalysts expected in the near future.